Not registered yet? Get a free account.
Sign UpYou're about to leave our website and go to an external link. Are you sure?
Biocon Biologics Limited, is an unlisted public company incorporated on 08 June, 2016. It is classified as a public limited company and is located in , Karnataka. It's authorized share capital is INR 3,500.00 cr and the total paid-up capital is INR 1,758.31 cr.
Biocon Biologics Limited's operating revenue range is Over INR 500 cr for the financial year ending on 31 March, 2024. It's book networth has increased by 3.82%.
Read more
** All rupee values in INR crores. Based on March 2024 numbers.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
* INR 349 for 20+ credits purchase
1 credit = one company dashboard
State | Type | Address |
---|
Designation | Name | DIN/PAN | Tenure |
---|---|---|---|
Director | Thomas Jason Roberts | 09337723 | 4 years |
Director | Daniel Mark Bradbury | 06599933 | 6 years |
Director | Nivruti Rai | 01353079 | 6 years |
Director | Bobby Kanubhai Parikh
Shareholder
|
00019437 | 6 years |
Director | Peter Baron Piot | 09015343 | 5 years |
Whole-time Director | Kiran Mazumdar Shaw | 00347229 | 9 years |
Director | Arun Suresh Chandavarkar
Shareholder
|
01596180 | 9 years |
Managing Director | Shreehas Pradeep Tambe | 09796480 | 3 years |
Nominee Director | Rajiv Malik | 00120557 | 3 years |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales | 1,768.8 | 1,940.8 | 2,362.5 | 2,092.4 | 3,093.3 |
Operating profit | 443.6 | 405.1 | 376.7 | -265.8 | 290.1 |
Net profit | 288.3 | 209.7 | 86.0 | -445.3 | 368.9 |
Gross margin | 70.7 | 67.6 | 66.3 | 62.5 | 65.8 |
Operating margin | 25.1 | 20.9 | 15.9 | -12.7 | 9.4 |
Net margin | 16.1 | 10.8 | 3.6 | -20.3 | 9.8 |
Networth | 1,015.3 | 2,049.3 | 2,120.6 | 16,785.6 | 17,426.0 |
Borrowings | 838.3 | 2,406.5 | 4,230.9 | 3,859.0 | 5,013.9 |
Assets | 4,898.9 | 6,843.4 | 7,353.9 | 22,749.9 | 24,534.4 |
Debt to equity | 0.8 | 1.2 | 2.0 | 0.2 | 0.3 |
Current ratio | 0.6 | 1.0 | 0.9 | 1.2 | 1.1 |
ROE | 28.4 | 10.2 | 4.1 | -2.6 | 2.1 |
Days payable | 360.0 | 309.0 | 225.0 | 415.0 | 198.0 |
WC days | -260.0 | -15.0 | -55.0 | 67.0 | 42.0 |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Equity Capital | 206.0 | 1,058.8 | 1,058.8 | 1,321.7 | 1,321.7 |
Reserves | 809.3 | 990.5 | 1,061.8 | 15,463.9 | 16,104.3 |
Borrowings + | 838.3 | 2,406.5 | 4,230.9 | 3,859.0 | 5,013.9 |
Long term borrowings | 565.0 | 2,128.3 | 2,353.8 | 2,774.8 | 2,928.2 |
Short term borrowings | 273.3 | 278.2 | 1,877.1 | 1,084.2 | 2,085.7 |
Trade payables + | 511.3 | 532.6 | 489.2 | 892.6 | 575.0 |
Days payable | 360.0 | 309.0 | 225.0 | 415.0 | 198.0 |
Other liabilities + | 3,045.3 | 2,387.6 | 1,002.4 | 2,105.3 | 2,094.5 |
Other non-current liabilities | 316.7 | 308.5 | 299.5 | 959.0 | 1,118.7 |
Other current liabilities | 2,217.3 | 1,546.5 | 213.7 | 253.7 | 400.8 |
Total liabilities | 4,898.9 | 6,843.4 | 7,353.9 | 22,749.9 | 24,534.4 |
Fixed Assets + | 1,838.8 | 2,453.7 | 2,996.9 | 3,097.3 | 3,304.1 |
Tangible assets | 677.7 | 852.3 | 874.0 | 2,024.2 | 1,966.9 |
CWIP | 1,152.6 | 1,592.4 | 2,095.2 | 1,057.1 | 1,222.8 |
Intangible assets | 8.5 | 9.0 | 27.7 | 16.0 | 114.4 |
LT loans and advances | - | - | - | - | - |
Other non-current assets | 1,318.9 | 2,114.3 | 2,135.4 | 17,039.0 | 17,813.6 |
Current assets + | 1,741.2 | 2,275.4 | 2,221.6 | 2,613.6 | 3,416.7 |
Inventories | 542.8 | 907.4 | 984.0 | 1,550.9 | 1,427.7 |
Trade receivables | 919.2 | 266.9 | 847.7 | 582.7 | 1,632.2 |
Cash and cash equivalents | 154.0 | 189.1 | 62.8 | 120.2 | 86.4 |
ST loans and advances | - | - | - | - | - |
Other current assets | 125.2 | 912.0 | 327.1 | 359.8 | 270.4 |
Total assets | 4,898.9 | 6,843.4 | 7,353.9 | 22,749.9 | 24,534.4 |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Sales + | 1,768.8 | 1,940.8 | 2,362.5 | 2,092.4 | 3,093.3 |
Sales growth % | None | 9.72 | 21.73 | -11.43 | 47.84 |
Expenses + | 1,463.9 | 1,690.9 | 2,200.1 | 2,710.6 | 3,333.9 |
Cost of goods | 517.7 | 628.9 | 795.0 | 784.5 | 1,059.1 |
Employee cost | 372.9 | 423.5 | 539.9 | 631.1 | 742.6 |
Other costs | 434.6 | 483.3 | 650.9 | 942.6 | 1,001.5 |
Operating profit + | 443.6 | 405.1 | 376.7 | -265.8 | 290.1 |
Operating margin % | 25.1 | 20.9 | 15.9 | -12.7 | 9.4 |
Other income | 22.3 | 6.3 | 10.3 | 96.9 | 681.4 |
Interest | 32.1 | 36.9 | 59.1 | 124.3 | 258.5 |
Depreciation | 106.6 | 118.3 | 155.2 | 228.1 | 272.2 |
Exceptional items | -3.8 | -12.1 | -80.4 | -3.8 | -8.2 |
Profit before tax | 323.4 | 244.1 | 92.3 | -525.1 | 432.6 |
Tax | 35.1 | 34.4 | 6.3 | -79.8 | 63.7 |
Profit - disc. ops | - | - | - | - | - |
Net profit | 288.3 | 209.7 | 86.0 | -445.3 | 368.9 |
Net margin % | 16.1 | 10.8 | 3.6 | -20.3 | 9.8 |
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Solvency + | |||||
Total Debt/Equity | 0.8 | 1.2 | 2.0 | 0.2 | 0.3 |
Net Debt/Equity | 0.7 | 1.1 | 2.0 | 0.2 | 0.3 |
Total Debt/Assets | 0.2 | 0.3 | 0.6 | 0.2 | 0.2 |
Total Assets/Equity | 4.8 | 3.3 | 3.5 | 1.4 | 1.4 |
Liquidity + | |||||
Current Ratio | 0.6 | 1.0 | 0.9 | 1.2 | 1.1 |
Quick Ratio | 0.4 | 0.6 | 0.5 | 0.5 | 0.7 |
Interest Coverage | 13.8 | 11.0 | 6.4 | -2.1 | 1.1 |
Performance | |||||
Gross Margin | 70.7 | 67.6 | 66.3 | 62.5 | 65.8 |
Operating Margin | 25.1 | 20.9 | 15.9 | -12.7 | 9.4 |
Net Margin | 16.1 | 10.8 | 3.6 | -20.3 | 9.8 |
Return + | |||||
Return on Equity | 28.4 | 10.2 | 4.1 | -2.6 | 2.1 |
Pre-tax ROCE | 58.3 | 12.1 | 8.4 | -14.2 | 0.5 |
Return on Assets | 5.9 | 3.1 | 1.2 | -2.0 | 1.5 |
Pre-tax ROIC | 19.8 | 6.7 | 3.5 | -2.4 | 0.1 |
Efficiency + | |||||
Days Payable | 360.0 | 309.0 | 225.0 | 415.0 | 198.0 |
Days Inventory | 383.0 | 527.0 | 452.0 | 722.0 | 492.0 |
Days Receivable | 190.0 | 50.0 | 131.0 | 102.0 | 193.0 |
Fixed Asset Turnover | 1.0 | 0.8 | 0.8 | 0.7 | 0.9 |
Total Asset Turnover | 0.4 | 0.3 | 0.3 | 0.1 | 0.1 |
Working Capital | |||||
Cash Conversion Cycle | 213.0 | 268.0 | 358.0 | 409.0 | 487.0 |
Working Capital Days | -260.0 | -15.0 | -55.0 | 67.0 | 42.0 |
Citicorp International Limited (through its authorized representative Citibank N.A. India)
No. of Loans: 1
Total Amount : 6,808.8 cr
Axis Trustee Services Limited
No. of Loans: 1
Total Amount : 2,734.9 cr
Name | Status | Paid up Capital | Common Directors | Address |
---|---|---|---|---|
BMR BUSINESS SOLUTIONS PRIVATE LIMITED |
Active
|
8.5 L | 1 | Maharashtra |
TAXAND ADVISORS PRIVATE LIMITED |
Strike Off
|
1.0 L | 1 | Delhi |
BMR GLOBAL SERVICES PRIVATE LIMITED |
Active
|
1.0 L | 1 | Delhi |
AVAANA CAPITAL ADVISORS LLP |
Active
|
13,333.0 | 1 | Maharashtra |
INDOSTAR CAPITAL FINANCE LIMITED |
Active
|
136.7 Cr | 1 | |
RELIANCE PETROLEUM LIMITED |
Amalgamated
|
4,500.0 Cr | 1 | |
INFOSYS LIMITED |
Active
|
2,077.2 Cr | 1 | Karnataka |
BIOCON LIMITED |
Active
|
668.5 Cr | 2 | Karnataka |
MYLAN LABORATORIES LIMITED |
Active
|
48.7 Cr | 1 | Telangana |
RAPIDUE TECHNOLOGIES PRIVATE LIMITED |
Active
|
19.2 Cr | 1 | Telangana |
BIOCON BIOPHARMACEUTICALS LIMITED |
Amalgamated
|
17.6 Cr | 2 | Karnataka |
CSEP RESEARCH FOUNDATION |
Active
|
1.0 L | 1 | Delhi |
NARAYANA VAISHNO DEVI SPECIALTY HOSPITALS PRIVATE LIMITED |
Active
|
1.0 Cr | 1 | Karnataka |
BIOCON RESEARCH LIMITED |
Active
|
5.0 L | 2 | Karnataka |
BIOCON BIOSPHERE LIMITED |
Active
|
288.6 Cr | 1 | Karnataka |
SCIENCE GALLERY BENGALURU |
Active
|
0.0 | 1 | Karnataka |
BIOFUSION THERAPEUTICS LIMITED |
Active
|
5.0 L | 1 | Karnataka |
GLENLOCH PROPERTIES LLP |
Active
|
1.0 L | 1 | Karnataka |
MAZUMDAR SHAW MEDICAL FOUNDATION |
Active
|
1.0 L | 1 | Karnataka |
NARAYANA HRUDAYALAYA LIMITED |
Active
|
204.4 Cr | 2 | Karnataka |
BIOCON PHARMA LIMITED |
Active
|
887.1 Cr | 1 | Karnataka |
KARNATAKA TECHNOLOGY AND INNOVATION MUSEUM FOUNDATION |
Active
|
1.0 L | 1 | |
INNOVERSE FOUNDATION |
Active
|
1.0 L | 1 | |
TRENT LIMITED |
Active
|
35.5 Cr | 1 | Maharashtra |
IMMUNEEL THERAPEUTICS PRIVATE LIMITED |
Active
|
4.6 L | 1 | Karnataka |
CLINIGENE INTERNATIONAL LIMITED |
Amalgamated
|
5.0 L | 1 | Karnataka |
BIOCON ACADEMY |
Active
|
5.0 L | 1 | Karnataka |
SYNGENE INTERNATIONAL LIMITED |
Active
|
402.9 Cr | 1 | Karnataka |
INVEST INDIA |
Active
|
1.0 Cr | 1 | Delhi |
MYNVAX PRIVATE LIMITED |
Active
|
6.0 L | 1 | Karnataka |
BIOLOGICAL E. LIMITED |
Active
|
5.0 Cr | 1 |
Name | State / Country | Incorporation Year | Paidup Capital |
---|---|---|---|
Biocon Biologics UK Limited | United Kingdom | - | - |
Biocon SDN BHD | Malaysia | - | - |
Biocon Biologics Healthcare SDN BHD | Malaysia | - | - |
Biocon Biologics Inc | United States | - | - |
Biocon Biologics Do Brasil Ltda | Brazil | - | - |
Biocon Biologics FZ LLC | United Arab Emirates | - | - |
Biosimilar Collaborations Ireland Limited | Ireland | - | - |
Biosilars Newco Limited, UK | United Kingdom | - | - |
Biocon Biologics Germany GmbH, Germany | Germany | - | - |
Biocon Biologics Canada Inc, Canada | Canada | - | - |
Biocon Biologics France | France | - | - |
Biocon Biologics Spain S.L.U, Spain | Spain | - | - |
Biocon Biologics Switzerland AG, Switzerland | Swaziland | - | - |
Biocon Biologics Belgium BV, Belgium | Belgium | - | - |
Biocon Biologics Finland OY, Finland | Finland | - | - |
Biocon Biologics Morocco S.A.R.L.A.U | Morocco | - | - |
Biocon Biologics Greece SINGLE MEMBER P.C. | Greece | - | - |
Biocon Biologics South Africa (Pty) Ltd. | South Africa | - | - |
Biocon Biologics (Thailand) Co., Ltd. | Thailand | - | - |
Biocon Biologics Philippines Inc. | Philippines | - | - |
Biocon Biologics Italy S.r.l | Italy | - | - |
Biocon Biologics Croatia LLC | Croatia | - | - |
Biocon SDN BHD, Malaysia | Malaysia | - | - |
Biocon Biologics Healthcare SDN BHD, Malaysia | Malaysia | - | - |
Biocon Biologics Inc., USA | United States | - | - |
Biosimilar Collaborations Ireland Limited, Ireland | Ireland | - | - |
Biosimilars Newco Limited, UK | United Kingdom | - | - |
Biocon Biologics France S.A.S, France | France | - | - |
Biocon Biologics Switzerland AG, Switzerland | Switzerland | - | - |
Biocon Biologics Belgium BV, Belgium | Belgium | - | - |
Biocon Biologics Spain S.L.U, Spain | Spain | - | - |
Biocon Biologics Finland OY, Finland | Finland | - | - |
Biocon Biologics Greece SINGLE MEMBER P.C | Greece | - | - |
Biocon Biologics (Thailand) Co., Ltd. | Thailand | - | - |
Biocon Biologics Morocco S.R.L | Morocco | - | - |
Biocon Biologics South Africa (Pty) Ltd. | South Africa | - | - |
BIOCON BIOLOGICS PHILIPPINES INC. | Philippines | - | - |
BIOCON BIOLOGICS ITALY S.R.L. | Italy | - | - |
Biocon Biologics Croatia LLC | Croatia | - | - |
Read more
The incorporation date of BIOCON BIOLOGICS LIMITED is 08 June, 2016
The authorized share capital of BIOCON BIOLOGICS LIMITED is INR ₹ 3,500.0 Cr.
The paid-up capital of BIOCON BIOLOGICS LIMITED is INR ₹ 1,758.3 Cr.
The registered address of BIOCON BIOLOGICS LIMITED is Biocon House, Ground Floor, Tower-3, Semicon Park Electronic City, Phase - II, Hosur Road, Bangalore, Bengaluru, Karnataka, India, 560100 - 560100
The CIN number of BIOCON BIOLOGICS LIMITED is U24119KA2016PLC093936.